- Home
- OBK vs PHVS Comparison
OBK vs PHVS Comparison
Compare OBK & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBK
- PHVS
- Stock Information
- Founded
- OBK 1912
- PHVS 2015
- Country
- OBK United States
- PHVS Netherlands
- Employees
- OBK N/A
- PHVS N/A
- Industry
- OBK Major Banks
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- OBK Finance
- PHVS Health Care
- Exchange
- OBK Nasdaq
- PHVS Nasdaq
- Market Cap
- OBK 1.0B
- PHVS 1.0B
- IPO Year
- OBK 2018
- PHVS 2021
- Fundamental
- Price
- OBK $33.15
- PHVS $18.56
- Analyst Decision
- OBK Buy
- PHVS Strong Buy
- Analyst Count
- OBK 5
- PHVS 5
- Target Price
- OBK $36.80
- PHVS $40.60
- AVG Volume (30 Days)
- OBK 161.1K
- PHVS 73.1K
- Earning Date
- OBK 01-22-2025
- PHVS 11-13-2024
- Dividend Yield
- OBK 1.80%
- PHVS N/A
- EPS Growth
- OBK N/A
- PHVS N/A
- EPS
- OBK 2.43
- PHVS N/A
- Revenue
- OBK $343,330,000.00
- PHVS N/A
- Revenue This Year
- OBK N/A
- PHVS N/A
- Revenue Next Year
- OBK $3.76
- PHVS N/A
- P/E Ratio
- OBK $13.69
- PHVS N/A
- Revenue Growth
- OBK N/A
- PHVS N/A
- 52 Week Low
- OBK $27.69
- PHVS $15.37
- 52 Week High
- OBK $37.56
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- OBK 48.99
- PHVS 51.83
- Support Level
- OBK $32.53
- PHVS $18.18
- Resistance Level
- OBK $33.66
- PHVS $19.88
- Average True Range (ATR)
- OBK 1.01
- PHVS 1.11
- MACD
- OBK -0.19
- PHVS 0.17
- Stochastic Oscillator
- OBK 34.70
- PHVS 76.86
About OBK Origin Bancorp Inc.
Origin Bancorp Inc is a financial holding company. The bank provides a broad range of financial services to businesses, municipalities, high-net-worth individuals, and retail clients. The bank principally operates in one business segment, community banking. The bank is engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans. The bank generates the majority of its revenue from interest earned on loans and investments, service charges, and fees on deposit accounts.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.